

To: (10)(2e) (10)(2e) (10)(2e) @rivm.nl]
From: (10)(2e)
Sent: Tue 5/26/2020 10:29:02 AM
Subject: COVID-19 diagnostics trial / study
Received: Tue 5/26/2020 10:29:29 AM
[NovaTec_GSD_NovaPrimeSARS-CoV-2.pdf](#)
[PCOV6033-eng.dt-20200514.pdf](#)
[P-50-CoVK41_s INGEZIM COVID 19 CROM \(TIRAS\) en.pdf](#)
[P-50-CoVK41 INGEZIM COVID 19 CROM \(DISPOSITIVOS\) en.pdf](#)
[Technical Sheet INgezim COVID 19 DR 220520 en .pdf](#)
[Technical sheet Ingezim COVID 19 CROM en 220520.pdf](#)

Dear (10)(2e) (10)(2e)

In addition to our COVID-19 antibody ELISAs (for IgA, IgG and IgM) we have recently launched a CE-marked RT-PCR as well as a lateral flow rapid test. I attached some information for these new parameters to this mail.

Currently we are looking for external study sites who are interested in conducting a study / trial of our test system. We are highly interested in your feedback in regards to the performance of our diagnostic test systems.

Are you interested in having a closer look on our diagnostic SARS-2 solutions? We would be happy to provide some kits for you and to start a discussion on how to establish a cooperation between us.

Looking forward for your feedback

Thanks a lot and best regards

(10)(2e)

(10)(2e)

(10)(2e)

Email: (10)(2e) @novatec-id.com

Phone: (10)(2e)

[novatec-id.com](#) | [LinkedIn](#)



**NovaLisa® SARS-CoV-2 (COVID-19)
IgA, IgG, and IgM**

NovaTec Immundiagnostica GmbH is now part of the Gold Standard Diagnostics Group

NovaTec Immundiagnostica GmbH, Waldstraße 23 A6 63128 Dietzenbach, Germany.

Managing Director: (10)(2e)

This Email may contain confidential and/or privileged information. If you are not the intended recipient or have received this Email in error please notify the sender immediately and destroy this Email. Any unauthorized copying, disclosure or distribution of the material in this Email is strictly forbidden.